David Kabakoff

David S.
Kabakoff was the founder of Salmedix, Inc. (founded in 2001) where he served as Chairman & Chief Executive Officer from 2001 to 2005.
Dr. Kabakoff was the founder of Amplimmune, Inc. (founded in 2007) where he served as Chairman.
Dr. Kabakoff is the founder of Strategy Advisors LLC (founded in 2001) where he served as President in 2011.
Current jobs include Chairman at NextCure, Inc. since 2015; Director at Biotheranostics, Inc.; Director at Antiva Biosciences, Inc. since 2015; Director at RareCyte, Inc.; Director at Rainier Therapeutics, Inc. since 2018; Director at Dauntless 1, Inc.; Director at Dauntless Pharmaceuticals, Inc.; Director at Dauntless 2, Inc.; Director at Neurana Pharmaceuticals, Inc.; Director at Intrepida Bio, Inc.; Executive Partner at Sofinnova Investments, Inc. since 2009; and Founding Senior Partner at Healthquest Capital Management Co LLC since 2013.
Former jobs include Chairman & Chief Executive Officer at Corvas International, Inc. from 1989 to 1996; President & Chief Executive Officer at Spiros Development Corp II, Inc.; Non-Executive Chairman at Cebix, Inc.; Chairman at Trius Therapeutics, Inc. from 2006 to 2013; Independent Director at InterMune, Inc. from 2011 to 2014; Director at Allylix, Inc.; Director at Principia Biopharma, Inc. from 2016 to 2018; Director at Avalon Pharmaceuticals, Inc. from 2006 to 2009; Treasurer & Director at Jewish Community Foundation of San Diego from 2012 to 2014; Independent Director at Castle Biosciences, Inc. from 2017 to 2021; Executive Vice President at Dura Pharmaceuticals, Inc. from 1996 to 2000; Vice President-Research & Development at Hybritech, Inc. from 1983 to 1989; and Board Member at Lineagen, Inc. Education includes undergraduate degree from Case Western Reserve University and doctorate from Yale University.